[{"id": "cMBaS3XhASkwf_quIAIaDogPxq_j-8ylnJi024di9WU", "publisher": {"name": "MarketWatch", "homepage_url": "https://www.marketwatch.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/marketwatch.svg", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/marketwatch.ico"}, "title": "Warren Buffett reportedly traded stocks that Berkshire Hathaway was trading", "author": "MarketWatch", "published_utc": "2023-11-09T17:00:00Z", "article_url": "https://www.marketwatch.com/story/warren-buffett-reportedly-traded-stocks-that-berkshire-hathaway-was-trading-9d0c8cf5", "tickers": ["BRK.B", "BRK.A", "WMT", "WFC", "JNJ"], "amp_url": "https://www.marketwatch.com/amp/story/warren-buffett-reportedly-traded-stocks-that-berkshire-hathaway-was-trading-9d0c8cf5", "image_url": "https://images.mktw.net/im-666323/social", "description": "Buffett has said he \u2018can\u2019t be buying\u2019 the same stocks as his company Berkshire Hathaway, but a new report calls that into question"}, {"id": "FKozmsKACkwd6-coIdtNf1yNCeQ1xWd6f-rBBocTm_o", "publisher": {"name": "The Motley Fool", "homepage_url": "https://www.fool.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/themotleyfool.svg", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/themotleyfool.ico"}, "title": "2 Magnificent Dow Stocks to Buy in November and 1 to Avoid Like the Plague", "author": "newsfeedback@fool.com (Sean Williams)", "published_utc": "2023-11-09T10:21:00Z", "article_url": "https://www.fool.com/investing/2023/11/09/2-dow-stocks-buy-in-november-1-avoid-like-plague/", "tickers": ["JNJ", "PG", "WBA"], "image_url": "https://g.foolcdn.com/editorial/images/753920/stock-market-ticker-symbol-digital-quote-board-nyse-sp-500-nasdaq-getty.jpg", "description": "Two of the Dow's 30 components are historically cheap, while concerns are mounting for another time-tested business.", "keywords": ["investing"]}, {"id": "80uqiUfe-CSrE7CmuRX7_2l2ODabvwkpVGA67BWYHtM", "publisher": {"name": "Zacks Investment Research", "homepage_url": "https://www.zacks.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/zacks.png", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/zacks.ico"}, "title": "Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates", "author": "Zacks Equity Research", "published_utc": "2023-11-08T17:26:00Z", "article_url": "https://www.zacks.com/stock/news/2181081/bayers-bayry-q3-earnings-and-revenues-miss-estimates", "tickers": ["REGN", "JNJ", "APLS"], "amp_url": "https://www.zacks.com/amp/stock/news/2181081/bayers-bayry-q3-earnings-and-revenues-miss-estimates", "image_url": "https://staticx-tuner.zacks.com/images/articles/main/e9/1435.jpg", "description": "Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook."}, {"id": "4OpNXEt3Hx4z4NG2sA44v9JtzICvR9huypioAmXiNCg", "publisher": {"name": "The Motley Fool", "homepage_url": "https://www.fool.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/themotleyfool.svg", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/themotleyfool.ico"}, "title": "3 Brilliant Artificial Intelligence Stocks to Buy and Hold Forever", "author": "newsfeedback@fool.com (George Budwell)", "published_utc": "2023-11-08T14:45:00Z", "article_url": "https://www.fool.com/investing/2023/11/08/3-brilliant-artificial-intelligence-stocks-to-buy/", "tickers": ["GEHC", "JNJ", "NVDA", "MDT"], "image_url": "https://g.foolcdn.com/editorial/images/754157/doctor-xray.jpg", "description": "Healthcare stocks are widely expected to be a prime beneficiary of the AI revolution. These three names could be the best of the bunch.", "keywords": ["investing"]}, {"id": "ZE4bk5Js8tO_6K3WkP4KRRWRDVtfpulsxs-boE4a5NY", "publisher": {"name": "Benzinga", "homepage_url": "https://www.benzinga.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/benzinga.svg", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/benzinga.ico"}, "title": "Jim Cramer Asks Why The World's Largest Healthcare Products Company Has 'An Ill-Advised Strategy'", "author": "Lisa Levin", "published_utc": "2023-11-08T13:35:41Z", "article_url": "https://www.benzinga.com/trading-ideas/long-ideas/23/11/35666275/jim-cramer-asks-why-the-worlds-largest-healthcare-products-company-has-an-ill-advised-st", "tickers": ["AGNC", "CSCO", "CLX", "JNJ", "VTR"], "amp_url": "https://www.benzinga.com/amp/content/35666275", "image_url": "https://cdn.benzinga.com/files/images/story/2023/11/08/jim_cramer_shutter4.jpg?width=1200&height=800&fit=crop", "description": "On CNBC\u2019s \"Mad Money Lightning Round,\" Jim Cramer said  The Clorox Company\u2019s  (NYSE: CLX) recent quarter was \"ok.\" He added, \"I think that the hack is behind them. I think Linda Rendle is  doing a very good job.\"\nAGNC Investment Corp.  (NASDAQ: AGNC) has \"been a dog so long,\" Cramer said, \"It\u2019s just been a value trap.\"\nCramer said  Cisco Systems, Inc.  (NASDAQ: CSCO) ...", "keywords": ["Long Ideas", "News", "Markets", "Media", "Trading Ideas"]}, {"id": "EHgFDiYNQxVGSo0zNpxLiaVAv_l-sROWZdHD7wkcp_Y", "publisher": {"name": "MarketWatch", "homepage_url": "https://www.marketwatch.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/marketwatch.svg", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/marketwatch.ico"}, "title": "Grab these 2 funds with rich 11%-12% yields while you can", "author": "MarketWatch", "published_utc": "2023-11-08T12:18:00Z", "article_url": "https://www.marketwatch.com/story/grab-these-2-funds-with-rich-11-12-yields-while-you-can-f2856fb2", "tickers": ["BLK", "BMEZ", "UNH", "LLY", "MRK", "ABBV", "JNJ", "BIGZ"], "amp_url": "https://www.marketwatch.com/amp/story/grab-these-2-funds-with-rich-11-12-yields-while-you-can-f2856fb2", "image_url": "https://images.mktw.net/im-879591/social", "description": "If you invest for income, consider taking advantage of these unusual opportunities."}, {"id": "vWRnQuwmNGfrhH9uKJmmgjxo0f7Kb_fTfa-IFZtaiT4", "publisher": {"name": "Zacks Investment Research", "homepage_url": "https://www.zacks.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/zacks.png", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/zacks.ico"}, "title": "Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag", "author": "Zacks Equity Research", "published_utc": "2023-11-07T16:21:00Z", "article_url": "https://www.zacks.com/stock/news/2180216/halozyme-halo-q3-earnings-top-estimates-revenues-lag", "tickers": ["BMY", "JNJ", "HALO"], "amp_url": "https://www.zacks.com/amp/stock/news/2180216/halozyme-halo-q3-earnings-top-estimates-revenues-lag", "image_url": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "description": "Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023."}, {"id": "Kyejjbz-KtWuCsPDAA_1FRjULGyiFa_ucjLUFXTMH24", "publisher": {"name": "The Motley Fool", "homepage_url": "https://www.fool.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/themotleyfool.svg", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/themotleyfool.ico"}, "title": "2 Magnificent Dividend Stocks Trading Near 52-Week Lows to Buy Now and Hold at Least a Decade", "author": "newsfeedback@fool.com (Cory Renauer)", "published_utc": "2023-11-07T10:37:00Z", "article_url": "https://www.fool.com/investing/2023/11/07/2-magnificent-dividend-stocks-trading-near-52-week/", "tickers": ["JNJ", "MO", "KVUE"], "image_url": "https://g.foolcdn.com/editorial/images/753925/couple-looking-at-stocks-on-tablet-getty.jpg", "description": "Taking advantage of the discounted prices these stocks have been trading at could do wonders for your passive income stream.", "keywords": ["investing"]}, {"id": "wUibrbahk7-zdFj1Vng-bkvlhnjdRiEKXNDLMAzkpVw", "publisher": {"name": "MarketWatch", "homepage_url": "https://www.marketwatch.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/marketwatch.svg", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/marketwatch.ico"}, "title": "The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman \u2013 and Martin Shkreli\u00a0", "author": "MarketWatch", "published_utc": "2023-11-06T20:32:00Z", "article_url": "https://www.marketwatch.com/story/the-doctor-lowering-drug-prices-for-1-million-patients-with-help-from-mark-cuban-sam-altman-and-martin-shkreli-5e72d77a", "tickers": ["JNJ", "PFE", "AMZN", "CVS", "CI", "CHRS", "ABBV", "AMGN", "AZN", "LLY", "UNH"], "amp_url": "https://www.marketwatch.com/amp/story/the-doctor-lowering-drug-prices-for-1-million-patients-with-help-from-mark-cuban-sam-altman-and-martin-shkreli-5e72d77a", "image_url": "https://images.mktw.net/im-871034/social"}, {"id": "RnkDrGwbvfbO4bsrRBRbIOz49FflcT5sJ-cBPYkefFs", "publisher": {"name": "MarketWatch", "homepage_url": "https://www.marketwatch.com/", "logo_url": "https://s3.polygon.io/public/assets/news/logos/marketwatch.svg", "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/marketwatch.ico"}, "title": "Eli Lilly chief scientific officer \u2018extremely optimistic\u2019 that major new Alzheimer\u2019s breakthrough is coming\u00a0", "author": "MarketWatch", "published_utc": "2023-11-06T16:05:00Z", "article_url": "https://www.marketwatch.com/story/eli-lilly-chief-scientific-officer-extremely-optimistic-that-major-new-alzheimers-breakthrough-is-coming-79003fcc", "tickers": ["LLY", "PFE", "MRK", "JNJ", "BIIB", "NVO"], "amp_url": "https://www.marketwatch.com/amp/story/eli-lilly-chief-scientific-officer-extremely-optimistic-that-major-new-alzheimers-breakthrough-is-coming-79003fcc", "image_url": "https://images.mktw.net/im-857606/social"}]